1. シグナル伝達
  2. Immunology/Inflammation
  3. Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most (clusters of differentiation)CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells[1][2].

Transmembrane Glycoprotein 関連製品 (368):

製品番号 製品名 製品効果 純度 構造式
  • HY-P991618
    ST2485 Inhibitor
    ST2485 is a monoclonal antitenascin antibody. ST2485 shows additivity in tenascin C binding in vitro as well as in a xenograft model. ST2485 binds human tenascin at an epitope partially shared with BC2. ST2485 cross-reacts with murine tenascin. ST2485 can be studied in antitumor research.
    ST2485
  • HY-P991798
    Anti-Mouse CD155 Antibody (4.24) Inhibitor
    Anti-Mouse CD155 Antibody (4.24) reacts with the mouse CD155. CD155 is a member of a subfamily of immunoglobulin-like adhesion receptors. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679).
    Anti-Mouse CD155 Antibody (4.24)
  • HY-P992459
    SGM-101 Antibody
    SGM-101 Antibody is a chimeric monoclonal antibody targeting carcinoembryonic antigen (CEA). SGM-101 Antibody can serve as a tumor-specific fluorescent imaging probe after being covalently conjugated with the near-infrared fluorescent dye BM104. SGM-101 Antibody accumulates in CEA-positive tumor tissues via antigen-antibody specific binding, and emits near-infrared fluorescence to enable imaging of tumor lesions. SGM-101 Antibody can be used in research related to gastric cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, peritoneal carcinomatosis, and liver metastases.
    SGM-101 Antibody
  • HY-P991643
    MTRX1011A Inhibitor
    MTRX1011A is a humanized IgG1 monoclonal antibody inhibitor targeting CD4. MTRX1011A can be used for rheumatoid arthritis (RA) research.
    MTRX1011A
  • HY-P990262
    Anti-Mouse CD8 Antibody (HB-129) Inhibitor
    Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD8. Anti-Mouse CD8 Antibody (HB-129) can deplete CD8+ T cells. Anti-Mouse CD8 Antibody (HB-129) can be used for the researches of cancer, inflammation, immunology and metabolic disease, such as P815 tumor, experimental autoimmune thyroiditis (EAT) and graft versus host disease (GVHD).
    Anti-Mouse CD8 Antibody (HB-129)
  • HY-P991896
    AT1412 Modulator
    AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells [1] .
    AT1412
  • HY-P992209
    Anti-CD318/CDCP1 Antibody (25A11) Inhibitor
    Anti-CD318/CDCP1 Antibody (25A11) is an anti-CDCP1 antibody. Anti-CD318/CDCP1 Antibody (25A11) drives the internalization of antibody-CDCP1 complexes, inhibits cancer cell migration and invasion, and blocks downstream migration/invasion signaling pathways. When conjugated with saponin, Anti-CD318/CDCP1 Antibody (25A11) mediates the killing of prostate cancer cells. When conjugated with saponin, this antibody acts as an immunotoxin to inhibit the growth and metastasis of primary prostate tumors in mouse xenograft models. Anti-CD318/CDCP1 Antibody (25A11) is applicable to prostate cancer-related research.
    Anti-CD318/CDCP1 Antibody (25A11)
  • HY-P992402
    MAI1738 Inhibitor
    MAI1738 is a human monoclonal antibody targeting PODXL. MAI1738 can be used for cancer-related research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    MAI1738
  • HY-P991894
    Anti-CD8 Antibody
    Anti-CD8 Antibody is an antibody against human CD8. Recommend Isotype Controls:?Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD8 Antibody
  • HY-P990852
    Anti-CEACAM7 Antibody (P3-7B) Inhibitor
    Anti-CEACAM7 Antibody (P3-7B) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CEACAM7. Anti-CEACAM7 Antibody (P3-7B) reacts with human carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7). Anti-CEACAM7 Antibody (P3-7B) can be used for detecting CEACAM7 in cancer.
    Anti-CEACAM7 Antibody (P3-7B)
  • HY-P991308
    TRX385 Antagonist
    TRX385 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. TRX385 can be used in anticancer and antiviral research.
    TRX385
  • HY-170955
    HA-CD44 interaction inhibitor 3 Inhibitor
    HA-CD44 interaction inhibitor 3 (compound 5d) is a Hyaluronic acid (HY-B0633A) (HA)-CD44 interaction inhibitor with antiproliferative activities. HA-CD44 interaction inhibitor 3 inhibits MDA-MB-231 (CD44++) cells and MCF-7 cells (CD44--) with EC50s of 4.24 μM and 14.74 μM, respectively. HA-CD44 interaction inhibitor 3 shows the potential for cancer research.
    HA-CD44 interaction inhibitor 3
  • HY-P991665
    MEN1112 Inhibitor
    MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC50=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML.
    MEN1112
  • HY-181738
    GPR17 agonist 2
    GPR17 agonist 2 (compound 10) is a human GPR17 agonist and selective P2Y receptor non-activator.GPR17 agonist 2 modulates intracellular cAMP levels through functional activation of its target receptor.GPR17 agonist 2 can be used for the research of multiple sclerosis, cerebral ischemia, traumatic brain injury, spinal cord injury.
    GPR17 agonist 2
  • HY-P992309
    Anti-TSPAN33 Antibody
    Anti-TSPAN33 Antibody is a monoclonal antibody targeting TSPAN33. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TSPAN33 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-TSPAN33 Antibody
  • HY-P991824
    Anti-Mouse CD4 Antibody (YTS 177) Inhibitor
    Anti-Mouse CD4 Antibody (YTS 177) reacts with the mouse CD4. Anti-Mouse CD4 Antibody (YTS 177) shows non-depleting but binding does induce rapid internalization of CD4 on both CD4+ Foxp3- T cells and Foxp3+ regulatory T cells. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679).
    Anti-Mouse CD4 Antibody (YTS 177)
  • HY-P992350
    EBC-129 Antibody
    EBC-129 Antibody is a specific antibody for the synthetic antibody-drug conjugate (ADC) EBC-129, which specifically targets CEACAM5 and CEACAM6 glycosylated at N256. EBC-129 Antibody can be used for the research of pancreatic ductal adenocarcinoma.
    EBC-129 Antibody
  • HY-P992179
    AM-928
    AM-928 is a human monoclonal antibody targeting EpCAM/TROP1/CD326. AM-928 possesses potential anti-tumor activity.
    AM-928
  • HY-P991307
    BND-35 Antagonist
    BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model.
    BND-35
  • HY-P992058
    Leukotuximab
    Leukotuximab (ART-140; EGX-040) is an anti-JL1 mAb and an anti-leukemic agent. Leukotuximab targets the JL1 epitope of CD43 and exerts cytotoxic effects on JL1-positive leukemia cells. Except for thymocytes and some bone marrow mononuclear cells, Leukotuximab causes no damage to most normal tissues. Leukotuximab can be used in the research of acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome.
    Leukotuximab